Accomplishments in 2012

In 2012, the Sickle Cell Cure Foundation broadened its network of collaborators and began making plans for launching the research necessary for regulatory approval for a new drug.

  • New strategic alliances were formed with:
    • A global consortium of chemical manufacturing operations, including pharmaceuticals.
    • I2E: an Oklahoma non-profit corporation for assisting entrepreneurs.
    • OCAST: the Oklahoma Center for Science and Technology.
    • EpimedX: a new business for facilitating the development of Gene Regulation Therapies (GRT).
    • Voices Organized in Civic Engagement(VOICE OKC), a community-based group dedicated to social action on health care and other issues.
  • New staff and collaborators
    • Frank R. Denton, PhD, MBA, JD became the SCCF patent attorney. His vitae includes patent officer and general council for Merck and other major pharmaceutical corporations.
    • Dr. Sunil K. Joshi, DVM teamed with Foundation and brings special skills in veterinary medicine and the design and interpretation of animal studies.
    • Jim McGoodwin, former Deputy Director of the Oklahoma State Office of Finance, volunteered time to the SCCF, authored several critical legal documents, and gave superb legal advice.
    • Clayton Duncan, Managing Director of Accele Venture Partners, and Rod Whitson, President of Bank 2, informally advised SCCF regarding the maturation process of the SCCF sickle-cell treatment into a clinical product.
    • Rick Rainey, OSCR director for I2E, Micheal Kindrat-Pratt, coordinator of SeedStep Angels, and Kenneth Knoll, manager of Concept Investments, provide financial and structural advice, including how to engage with potential investors, as part of the I2E collaboration. During October-December, potential investors were engaged based on this advice and with the assistance of Rod Whitson, and I2E.
    • Rick Rainey of I2E worked with Drs. Broyles and Floyd to engage Mark and Katherine Henry of Grow, LLC for assistance with the preparation of a Small Business Innovation Research (SBIR) proposal.
    • On March 11, 2012, Dr. Carol Curtis, I2E intern and senior research associate at the Oklahoma Medical Research Foundation, began working full time in the laboratory and guiding Drs. Floyd and Broyles on the SBIR proposal. Dr. Curtis had previously worked as a volunteer since June.
    • The Oklahoma Blood Institute and SCCF staff began discussing a potential collaboration for clinical trials on June 6, 2012.
    • Patrick A. Floyd began working as lab assistant, financial manager and accountant in July.
    • Larry Kennedy, with experience in both for-profit and non-profit institutions, gave Drs. Broyles and Floyd advice on structuring a legal and fruitful relationship between SCCF and EpimedX.
  • Scientific presentations and progress reports.
    • Numerous presentations with I2E, beginning April 2012.
    • East-to-West-Coast Iron Club (formerly East Coast Iron Club), UCLA, Oct 25-26.
    • Sickle Cell Anemia Awareness Benefit organized by the University of Oklahoma ΔƩƟ sorority and the IΦΘ fraternity.
    • Presentation at the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Dec 19, 2012.
    • Presentation to graduate students in the University of Oklahoma Biomedical Sciences Program, March, 2012.
  • Development of plans for continuation of testing in mice and new testing with baboons.
    • April 22, 2012, SCCF submitted a renewal application for continued drug testing in mice to the Institutional Animal Care and Use Committee (IACUC). The IACUC is an independent oversight body that functions similar to an Internal Review Board (IRB) for research involving testing with humans.
    • SCCF received the sixth annual approval of its Internal Review Board for Protection of Human Subjects protocol with Children’s Hospital of Oklahoma in November, 2012.
    • Dr. Gary White, Chief of Comparative Medicine at the University of Oklahoma Health Sciences Center, consulted with Dr. Broyles regarding testing of the SCCF GRT approach with baboons as a model for humans, March 2012. This partnership continues.
    • Dr. Don Lavelle, University of Illinois Chicago, advised Dr. Broyles regarding testing in baboons as a surrogate for humans to study the safety and efficacy of our GRT approach.
    • An interested agricultural company, that had signed a letter of intent and collaboration with SCCF during 2011, agreed to contribute funding for animal testing. An agreement was signed in December 2012 to jointly fund animal trials in mice and baboons of the SCCF treatment.

 

Comments

  1. Abena Amponsah says:

    I come from Ghana and living in Japan. I just find out that my two to three year boy is sickle cell aneamic. I’m in pain and angry for all these why I don’t know my son desease and to do anything to help him. Here in Japan they don’t do blood test on babies for this evil desease. What makes me more angry is that, for the past 6 month since he got sick they could not figured what was wrong just to give me cough and running nose drugs and sent me back home. I visit hospital almost every 5 days not until one day he was admitted that he had pneumonia and during the blood test they found out that.

    It just give me hope to see that there are people out there who care to look for cure. All what I can say is that we are with you in prayers that God will give you more wisdom and strength to fight this fight for us thank you very much.

Speak Your Mind

*